Product Reports Resources Pricing Login Book a demo

Biotalys

Food · Ghent, Belgium · Founded 2012

Protein-based biocontrol solutions for sustainable crop protection MoreLess

Biotalys is an agricultural technology (AgTech) company that develops protein-based biocontrol solutions to provide a sustainable and safe food supply. The company was founded in 2013 as AgroSavfe, a spin-off from the Flanders Institute for Biotechnology (VIB) and Vrije Universiteit Brussel (VUB), based on the research of Professor Jan Steyaert. It officially rebranded to Biotalys in 2019.

The company's core technology is the AGROBODY Foundry™ platform, which is based on llama-derived single-domain antibody technology (Nanobody®). This platform develops biocontrols that aim to combine the effectiveness of conventional chemical pesticides with the safety profile of biologicals. These solutions are designed to protect against crop pests and diseases both before and after harvest, helping to reduce food waste and improve yield. The company's initial product candidate, a biofungicide named EVOCA™, is developed to combat major fungal diseases like Botrytis cinerea and powdery mildew in fruits and vegetables. EVOCA is currently under regulatory review in the United States and the European Union, with a decision in the U.S. expected by the end of September 2025 and in the EU by the second half of 2026.

Biotalys operates in the AgTech market, providing solutions for growers of high-value crops. Its business model focuses on research and development, forming strategic partnerships for commercialization. A key collaboration includes a partnership with Syngenta to develop a new bioinsecticide. While the company has not yet generated revenue from product sales, its income is derived from R&D tax incentives and grants, including support from the Bill & Melinda Gates Foundation. The company went public in July 2021, listing on the Euronext Brussels stock exchange under the ticker BTLS to fund its product pipeline and commercialization efforts.

Patrice Sellès served as CEO from July 2019, leading the company through its IPO and initial commercial preparations. In 2023, Kevin Helash was appointed CEO to guide the company's next growth phase. The company is headquartered in Ghent, Belgium, and maintains a subsidiary in the United States.

Keywords: agricultural technology, biocontrols, crop protection, protein-based solutions, AGROBODY Foundry, sustainable agriculture, biofungicide, food supply chain, agtech, VIB spin-off, pest management, Botrytis, powdery mildew, EVOCA, food safety, post-harvest, biological pesticides, farm-to-fork, Nanobody technology, Euronext Brussels, biopesticides, crop science, food security

Valuation $100–500M
Revenue $10–50M
Headcount <100
Total funding $50–100M
Unlock exact values This page shows ranges. Dealroom has the exact numbers for Biotalys and the history behind them.

Company overview

Biotalys company information

The essential company record, classifications and operating signals in one place.

Status
Operational
Founded
2012
Headquarters
Ghent, Belgium
Employees
51
Open positions
None listed
Dealroom signal
64.1
client focusb2btechnologyDeep Techsub industryAgriTechbusiness modelSaaSsectorBiotechnologysectorCrop ProtectionsectorPest ControlsectorBiopesticidessectorSpinoutsectorSustainable Development GoalssectorRegenerative AgriculturesectorClimate TechsectorHard TechsectorClimate Adaptation

Valuation & funding

Biotalys funding history

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
PRIVATE PLACEMENT VCEquity / VC May 2026 $13M Gimv · SFPIM · PMV · Sofinnova Partners
PRIVATE PLACEMENT NON VCOther financing Oct 2024 $17M A.S.R. Asset Management · Ackermans & van Haaren
IPOExit Jul 2021 $55M $55M Undisclosed
GRANTOther financing Oct 2020 $1.2M VLAIO- Team Bedrijfstrajecten Crossroads France-Wallonie-Vlaanderen
GRANTOther financing May 2020 $1.8M VLAIO- Team Bedrijfstrajecten Crossroads France-Wallonie-Vlaanderen
SERIES CEquity / VC Mar 2020 Novalis Lifesciences
SERIES CEquity / VC Jul 2019 PMV · Qbic Fund · Madeli Participaties · Sofinnova Partners
SERIES BEquity / VC Mar 2017 Sofinnova Partners · Agri Vie · Globachem · Madeli Participaties
SERIES BEquity / VC Sep 2016 Gimv · PMV · Qbic Fund · Agri Investment Fund
SERIES AEquity / VC Jan 2013 SoFi · Qbic · Gimv · Flanders Institute for Biotechnology
Showing 10 recorded eventsUnlock the complete deal history →

Financials

Revenue, earnings and profit over time

Reported history and available estimates. Estimated years are marked “E”; sparse fields are left blank rather than inferred.

YearRevenueGrowthEBITDAMarginProfitMarginR&D
2026 $15M −$18M -125% −$19M -133.7% $15M
2025 $0 −$15M −$17M $15M
2024 $0 −$12M −$15M $12M
2023 $0 −$20M $18M
2022 $0 -100% −$23M
2021 $4.4M 0% −$18M -412.5%
2020 $4.4M −$14M -307.8%
Company filings, research estimates and Dealroom dataOpen the full financial model →

Growth signals

Biotalys website traffic

Latest recorded traffic for Biotalys is 8.2K monthly website visits, up 49.1% over the last three months. Biotalys's team declined 26.1% over the past year.

Latest monthly visits8.2K 3-month web change+49.1% 1-year team growth-26.1%
Monthly website visits76 observations · Mar 2020–Jul 2026
Hover or focus a point to see its exact monthly valueCompare with peers →

Comparisons

Biotalys compared with similar companies

Dealroom’s weighted taxonomy model identifies the closest operating peers. Company identity and context stay open; selected comparison metrics preview what is available in the platform.

Showing 8 of the closest matchesCompare every metric →

Talent graph

Biotalys's talent

Book a demo to see the people
Team profiled 13 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 3 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Investors

20 investors on Biotalys's cap table

Sourced from Dealroom's funding and investor records. Investor profile links are shown where available.

Seed 1 investor entered at this stage
VLAIO- Team Bedrijfstrajecten Crossroads France-Wallonie-Vlaanderen
Series A 12 investors entered at this stage
SoFi
Qbic
Gimv
Flanders Institute for Biotechnology
PMV
Qbic Fund
Agri Investment Fund
Cell Culture Company
Globachem
Sofinnova Partners
Agri Vie
Madeli Participaties
Series B+ 3 investors entered at this stage
Ackermans & van Haaren
K&E
Novalis Lifesciences
Other known 4 additional known investors
A.S.R. Asset Management
biotope by VIB
SFPIM
Vrije Universiteit Brussel

Global footprint

Where Biotalys has talent and traffic

Workforce by country
5 countries with
team presence
🇧🇪 Belgium84.8%
🇺🇸 United States8.7%
🇨🇭 Switzerland2.2%
🇵🇹 Portugal2.2%
🇫🇷 France2.2%
5 countries shown

In the news

Latest news about Biotalys

Recent press, funding announcements, and product moves mentioning Biotalys — open to read from the original sources.

See all news

Market sentiment

What the market is saying about Biotalys

An AI-synthesized read of the highest-engagement posts about Biotalys on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Biotalys’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.